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NADPH oxidaseImmune complex (IC) deposition in tissues triggers the release of harmful oxidant and lytic compounds by neu-
trophils. We examined how ten 3-phenylcoumarin derivatives affect the reactive oxygen species (ROS) produc-
tion by IC-stimulated human neutrophils. Most of the 3-phenylcoumarins inhibited the luminol-enhanced
chemiluminescence (CL-lum) more strongly than they inhibited the lucigenin-enhanced chemiluminescence
(CL-luc), without clear signs of toxicity. The most effective CL-lum inhibitors, 6,7-dihydroxy-3-
[3′,4′-methylenedioxyphenyl]-coumarin (5) and 6,7-dihydroxy-3-[3′,4′-dihydroxyphenyl]-coumarin (19), also
inhibited myeloperoxidase activity more potently and had higher hypochlorous acid scavenging ability, but
did not affect the NADPH-oxidase activity. The type, number, and position of the substituent inﬂuenced the phar-
macological effects of 3-phenylcoumarins; however, the structural requirements for CL-lum and CL-luc inhibi-
tion were a little different. Compounds 5 and 19 are promising prototypes of therapeutic molecules to
modulate ROS production by neutrophils in IC-mediated inﬂammatory diseases.
© 2013 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
The organism continuously produces antigen–antibody immune
complexes (IC) in response to foreign antigens, infection, and tissue in-
jury. By binding to erythrocytes, IC are transported to the spleen and
liver and further cleared from the circulation. However, increased IC for-
mation and defects in the IC clearancemechanism culminate in IC depo-
sition in vessels and tissues, which activates the complement system
and chemotaxis of inﬂammatory cells [1,2]. Fcγ and complement recep-
tors mediate the neutrophil activation at the inﬂammatory site,chemiluminescence; CL-luc,
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vier OA license.triggering phagocytosis, degranulation, and reactive oxygen species
generation (ROS) via the NADPH oxidase complex andmyeloperoxidase
(MPO) [3].Microbial killing depends on inﬂammatory cells releasing ox-
idant and lytic compounds; however, these compounds can damage the
surrounding tissues and impair the target organ function [4]. For in-
stance, IC deposition in tissues is strongly associated with rejection of
transplanted organs and initial response of autoimmune diseases such
as rheumatoid arthritis, systemic lupus erythematosus, and rheumatic
fever [2].
Neutrophils play a fundamental role in host defense and acute in-
ﬂammatory responses. To regulate autoimmune inﬂammation, it is im-
portant that neutrophils produce adequate amounts of ROS. Moreover,
neutrophils have an important part in chronic inﬂammatory responses
[5–7]. In this sense, modulating neutrophil ROS production is a promis-
ing therapeutic strategy to manage inﬂammation and reduce the dele-
terious effects of the over-activation of immune system cells in many
diseases [5,8,9]. Our research team has investigated the pharmacologi-
cal effects of natural and synthetic compounds like ﬂavonoids [10–12],
coumarins [13–15], and sesquiterpene lactones [16]. We have sought
to understand structure–activity relationships, unravel themechanisms
of action of these compounds, and discover prototypes of compounds
that can act as modulators of the effector functions of neutrophils in
IC-mediated inﬂammatory diseases.
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that occur in plants and microorganisms, and they display a wide
range of biological activities [17,18]. The last ten years have seen intense
work on the chemicalmodiﬁcation of the coumarin skeleton, in order to
obtain more potent antioxidant and anti-inﬂammatory compounds
[13,15,19–23]. The addition of a 3-phenyl ring and hydroxyl groups to
the coumarin molecule yields hydroxylated 3-phenylcoumarin deriva-
tives, known for their increased antioxidant effect [14,24] and ability
to inhibit peroxidases [14] and lipoxygenase [24]. These properties re-
veal the potential anti-inﬂammatory activity of these derivatives.
Higher plants produce 3-phenylcoumarins by the same biosynthetic
pathway that ﬂavonoids are generated, so these coumarins are consid-
ered a subclass of isoﬂavonoids [25]. 3-Phenylcoumarins exhibit antimi-
crobial [26,27], antiviral [28], antidepressant [29], anticoagulant [30],
and vasorelaxant [31] actions. Furthermore, they inhibit the glyceralde-
hyde 3-phosphate dehydrogenase of Trypanosoma cruzi [32],monoamine
oxidase [33] and tyrosinase [34].
Recently, we screened the inhibitory effect of a series of 3-
phenylcoumarin derivatives in the oxidative metabolism of rabbit
IC-stimulated neutrophils [15]. The qualitative and quantitative struc-
ture–activity relationship analysis allowed us to select promisingmodu-
lators of this neutrophil effector function. To continue investigating the
immunomodulating potential of 3-phenylcoumarins, in this study we
evaluated the inhibitory effect of ten selected 3-phenylcoumarin deriva-
tives bearing free and acetylated hydroxyl groups on O2•− generation
and total ROS production by IC-stimulated human neutrophils. We also
investigated possiblemechanisms underlying the pharmacological effect
of these compounds, such as their inhibitory activity toward NADPH ox-
idase andMPO aswell as their hypochlorous acid (HOCl) scavenging and
cytotoxic potential.2. Results
2.1. Inhibition of ROS production by neutrophils
First, we used the CL-luc and CL-lum assays to screen the inhibitory
effect of ten 3-phenylcoumarin derivatives (at 20 μM) on the O2•− andFig. 1. Chemical structures of 3-phenylctotal ROS generation by IC-stimulated neutrophils, respectively. Com-
paredwith the control, all the tested compounds had a signiﬁcant inhib-
itory effect on both CL-lum and CL-luc (Fig. 2a and b). In general, the
3-phenylcoumarin derivatives inhibited the neutrophil CL-lum more
strongly than they inhibited the neutrophil CL-luc; only compounds 1,
7, and 9 inhibited CL-lum and CL-luc to the same degree.
Next, we selected the compounds that inhibited CL-lum (1, 5, 6, 19,
and 20) or CL-luc (1, 5, 19, and 20) by more than 50% and investigated
their mechanism of action. The aforementioned derivatives inhibited
the IC-stimulated neutrophil CL-lum (Fig. 2c) and CL-luc (Fig. 2d) in a
concentration-dependent manner; their IC50 values are reported in
Table 2.
Compounds bearing the catechol group (5 and 19) inhibited
CL-lum the most effectively, but acetylation of their free hydroxyls
decreased their inhibitory potency by three- to fourfold (5 vs. 6; 19
vs. 20) (Table 2). Compounds 5 and 19 had signiﬁcantly lower IC50
values than quercetin. The non-substituted compounds 7 and 8 and
the monosubstituted compounds 9 and 10 were the least active —
they inhibited nearly 30% of CL-lum. Compounds 1 and 2 inhibited
around 70% and 45%, respectively, of CL-lum at the highest concentra-
tion tested herein (20 μM) (Fig. 2a).
Compound 5 inhibited CL-luc the most strongly: it was three times
more effective than quercetin and ﬁve to six times more effective
than compounds 1, 19, and 20, which had similar inhibitory effects
(Table 2). The hydroxylated 3-phenylcoumarin derivatives had signif-
icantly higher inhibitory activity than their acetylated counterparts
(1 vs. 2; 5 vs. 6; 9 vs. 10) (Fig. 2b). Compounds 8 and 10 were the
least effective. Compounds 2, 6, 7, and 9 inhibited only 30–40% of
CL-luc at 20 μM (Fig. 2b).
For most of the 3-phenylcoumarin derivatives, the presence of the
3′,4′-methylenedioxyl group enhanced the inhibition of neutrophil
CL-luc (1 vs. 9; 2 vs. 10; 5 vs. 19; 7 vs. 8). In the case of the
monosubstituted 3-phenylcoumarin derivatives, this same substitu-
ent increased the inhibition of neutrophil CL-lum (1 vs. 9; 2 vs. 10)
(Fig. 2, Table 2).
Together, these results suggest that the type, number, andposition of
the substituent inﬂuence the inhibitory effect of 3-phenylcoumarins on
ROS production by IC-stimulated neutrophils. However, the structuraloumarin derivatives and quercetin.
Fig. 2. Inhibitory effect of 3-phenylcoumarin derivatives on the human neutrophil reactive oxygen species generation, triggered by immune complexes, and assessed by luminol-
and lucigenin-enhanced chemiluminescence assays (CL-lum and CL-luc, respectively). Graphs a–b: Comparative effect of the ten 3-phenylcoumarins at 20 μM and quercetin at
10 μM on neutrophil CL-lum (graph a) and CL-luc (graph b). Graphs c–d: Concentration-dependent plots of quercetin (Q) and the 3-phenylcoumarins showing the highest inhib-
itory effects on neutrophil CL-lum (graph c) and CL-luc (graph d). Results are expressed as mean±SD of at least three independent experiments, assayed in duplicate. Statistics:
values not sharing the same letter (a–d) are signiﬁcantly different from each other (pb0.05; ANOVA and Tukey's post-hoc test).
Table 1
Viability of neutrophils after treatmentwith 3-phenylcoumarin derivatives andquercetina.
Compoundb Viable cells (%)c Released LDH (%)d
HBSS 97.5±0.9 5.7±1.1
DMSO 96.6±1.3 6.7±2.4
1 95.5±2.0 3.4±1.2
2 96.5±1.0 3.4±1.5
5 95.0±2.0 6.7±2.6
6 95.3±2.9 5.1±0.7
7 96.0±1.0 6.5±2.8
8 96.7±1.0 6.5±2.7
9 97.9±0.7 3.9±1.3
10 96.4±1.3 2.9±0.5
19 95.0±1.8 8.4±1.0
20 95.0±2.5 5.9±2.2
Quercetin 96.6±3.2 3.7±1.5
a Data represent themean±SDof three independent experiments assayed induplicate.
b HBSS: Hank's Balanced Salt Solution (untreated cells); DMSO: dimethyl sulfoxide
(0.1% v/v; vehicle control); 3-phenylcoumarin derivatives 1–20 tested at 20 μM;quercetin
tested at 10 μM.
c Cell viability determined by the Trypan Blue exclusion test with a total of 200 cells
counted for each sample.
d Values represent relative amounts of LDH released into the supernatant compared
with neutrophils completely lysed by Triton X-100.
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phenylcoumarin derivatives were a little different.
2.2. Cytotoxicity studies
Compared with the control, the ten 3-phenylcoumarin derivatives
and quercetin did not induce signiﬁcant LDH release or decrease neu-
trophil viability (Table 1). Thus, these compounds are not cytotoxic
under the assessed conditions.
2.3. Inhibition of NADPH oxidase activity
We measured the cellular O2 consumption, in order to ﬁnd out
whether the 3-phenylcoumarin derivatives modulate the NADPH oxi-
dase activity in IC-stimulated neutrophils. We tested compounds 1, 5,
19, and 20, which displayed the highest inhibitory effects on the
IC-stimulated neutrophil CL-luc. The four compounds inhibited the
NADPH oxidase activity in a similar way, but they were signiﬁcantly
less efﬁcient than quercetin and DPI (pb0.05, Table 3). Therefore, the
tested 3-phenylcoumarin derivatives have low inhibitory effect on the
NADPH oxidase activity of IC-stimulated neutrophils.
2.4. Inhibition of myeloperoxidase activity
We investigated whether the 3-phenylcoumarin derivatives with
the highest inhibitory effects on the IC-stimulated neutrophil CL-lum
(1, 5, 6, 19, and 20) inhibited MPO activity.
Surprisingly, compound 19 inhibited MPO activity twice more
effectively than the other tested compounds (pb0.05), including thestandard MPO inhibitor p-AB and the ﬂavonoid quercetin (Table 3).
Concentration-dependent plots of compound 19 and p-AB revealed sim-
ilar inhibitory effects at concentrations up to 12 μM, followed by in-
creased effect of compound 19 at higher concentrations (data not
shown).
Table 2
Inhibitory effect of the 3-phenylcoumarin derivatives on the reactive oxygen species
generation by immune complex-stimulated human neutrophils.
Compound IC50 (μM)
CL-lum CL-luc
1 10.44±3.14a 7.48±2.45a
5 1.05±0.16b,d 1.28±0.05b,⁎
6 4.06±0.72c >20
19 0.73±0.23b 6.98±2.61a,⁎
20 2.01±0.85d,e 8.32±1.51a,⁎
Quercetin 3.37±0.43c,e 4.05±0.47c
IC50 is the concentration inhibiting the luminol- or lucigenin-enhanced chemilumines-
cence (CL-lum or CL-luc, respectively) by 50%. Data are expressed as mean±SD of at
least three independent experiments, assayed in duplicate. Statistics: values in a column
not sharing the same letter (a–e) are signiﬁcantly different from each other (pb0.05;
ANOVA and Tukey's post-hoc test).
⁎ pb0.01 (CL-lum vs. CL-luc; Student's t test).
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tively than quercetin (pb0.05). Compound1was as effective as quercetin.
Comparedwith the control, the acetylated 3-phenylcoumarin derivatives
6 and 20 did not inhibit MPO signiﬁcantly under the assessed conditions.
Together, these results suggest that the hydroxylation pattern of the phe-
nolic compound is important for efﬁcient MPO activity inhibition.
2.5. Hypochlorous acid scavenging assay
We assayed the HOCl scavenging potential of the ﬁve 3-
phenylcoumarin derivatives (compounds 1, 5, 6, 19, and 20) with the
highest inhibitory effects on the neutrophil CL-lum in a cell-free system.
The tested derivatives showed concentration-dependent effects, and
compound 19 scavenged HOCl the most effectively (Table 3). Com-
pound 5 scavenged HOCl as effectively as quercetin, signiﬁcantly more
effectively than compounds 1 and 20, but around three times less effec-
tively than compound 19. Although we were not able to determine IC50
for compound 6, concentration-dependent plots revealed that it scav-
enged around 45% of the HOCl added to the reaction medium at
12 μM, the highest concentration tested (data not shown). Together,
these results suggest that the number and position of free hydroxyls de-
termine the biological activity of 3-phenyl coumarins, and that the acet-
ylated derivatives also scavenge HOCl effectively.
3. Discussion
In the present study we assessed whether ten 3-phenylcoumarin de-
rivatives inhibit the ROS generation by IC-stimulatedhumanneutrophils,Table 3
Inhibitory effect of the 3-phenylcoumarin derivatives on the activities of NADPH oxidase
and myeloperoxidase and their HOCl scavenging potentiala.
Compoundb NADPH oxidase
inhibition (%)
MPO inhibition
(%)
HOCl
scavenging
IC50 (μM)c
1 6.17±2.84a 18.76±5.37a 5.01±0.83a
5 3.20±1.38a 34.25±5.43b 3.75±0.80b
6 n.t 1.66±0.92c >12
19 4.31±2.08a 53.92±4.09d 1.03±0.23c
20 4.68±2.38a 6.44±2.62e 5.02±0.65a
Quercetin 18.25±4.93b 23.31±3.99a 3.19±0.08b
DPI 99.90±0.10c n.t n.t
p-AB n.t 31.20±3.15b n.t
a Data expressed asmean±SD of three independent experiments assayed in duplicate;
n.t.: not tested.
b Quercetin and 3-phenylcoumarins tested at 20 μM; DPI: diphenyliodonium chloride
(1 μM, speciﬁc inhibitor of NADPH oxidase), p-AB: p-aminobenzohydrazide (20 μM, spe-
ciﬁc inhibitor of MPO).
c IC50 is the concentration that scavenged 50% of the HOCl added to the reaction medi-
um. Statistics: values in a column not sharing the same letter (a–e) are signiﬁcantly differ-
ent from each other (pb0.05; ANOVA and Tukey's post-hoc test).investigated some of the underlyingmechanisms of action of these com-
pounds, and discuss the most relevant structural features for each
assessed biological activity. We used the chemiluminogenic probes
lucigenin and luminol to study how the 3-phenylcoumarin derivatives
affect the different steps of ROS generation by neutrophils. Lucigenin
speciﬁcally detects O2•−, the ﬁrst ROS produced via the NADPH oxidase
complex; luminolmeasures the overall ROS generation, with higher sen-
sitivity for the ROS originated from theMPO–H2O2–halide system in sub-
sequent steps [35].
All the tested compounds inhibit neutrophil CL-luc and CL-lum to
some extent, but this effect is not related to toxicity of the
3-phenylcoumarins on these cells, at least under the assessed condi-
tions. This result agrees with a previous work that reported the lack
of 3-phenylcoumarins cytotoxicity on rabbit neutrophils [15].
In general, the presence of free hydroxyls determines CL-luc and
CL-lum inhibition. Indeed, acetylation of this group decreases the inhib-
itory potency of most derivatives. In addition, the most active com-
pounds (5, 6, 19, and 20) bear at least one catecholic or o-diacetoxyl
group, indicating that this spatial disposition of the substituents favors
the inhibitory effect. The catechol group improves the inhibitory effect
of coumarins on superoxide anion generation by rat neutrophils [17]
as well as the antioxidant activity of coumarins [36]. On the other
hand, addition of the acetyl group to monohydroxylated compounds
does not affect inhibition of the rabbit neutrophil respiratory burst
[13], but acetylation of the free hydroxyls of polyphenols increases the
anti-inﬂammatory effect of these molecules. This structural modiﬁca-
tion enhances inhibition of prostaglandin synthesis and nitric oxide
production by macrophages and prevents ICAM-1 expression by endo-
thelial cells [37,38].
Interestingly, most compounds bearing the 3′,4′-methylenedioxyl
group (1, 2, 5, and 7) inhibit CL-luc signiﬁcantly more effectively than
the ones lacking this group (8, 9, 10, and 19). Substitution of the
3′,4′-diacetoxyl group (20) for the 3′,4′-methylenedioxyl group (6) sup-
presses the inhibitory effect of the 3-phenylcoumarin derivatives on
CL-luc. These results suggest that the presence of the catechol group as
well as the size and lipophilicity of the molecule are important for
CL-luc inhibition. It is noteworthy that (1) compounds 7 and 8 do not
have any substituents; (2) compounds 2 and 10 contain one or two hy-
droxyls; and (3) compounds 1, 5, 9, and 19 bear one or two hydroxyls as
well as a 3′,4′-methylenedioxyl group, whichmakes themolecule more
lipophilic. Moreover, the 3′,4′-methylenedioxyl group attached to the
3-phenyl ring forms a planar structure, the 3-piperonyl group, which
can favor interaction of the molecule with the membrane lipid bilayer,
thus facilitating entrance of the 3-phenylcoumarin derivative into the
intracellular environment.
Regarding CL-lum, the additional presence of the 3′,4′-meth-
ylenedioxyl group improves the inhibitory ability of the mono-
substituted compounds (1 vs. 9, 2 vs. 10), but it does not in-
ﬂuence the inhibitory ability of the non-substituted (7 vs. 8) or
the 6,7-dihydroxylated (5 vs. 19) compounds. Moreover, substitution
of the 3′,4′-diacetoxyl group (20) for the 3′,4′-methylenedioxyl group
(6) slightly decreases the inhibitory effect on CL-lum. These data indi-
cate that the presence of vicinal hydroxyl groups, free or acetylated, is
the most important structural feature for signiﬁcant CL-lum inhibition.
Compound5, which bears 6,7-dihydroxyl and3′,4′-methylenedioxyl
groups, inhibits the two steps of neutrophil ROS generation themost ef-
fectively; it also gives similar IC50 values for CL-lum and CL-luc. There-
fore, the hydrogen-donor ability and lipophilicity of the molecule
contribute to inhibiting the two main steps of ROS production by
IC-stimulated human neutrophils. Compounds 6, 19, and 20 seem to
modulate this neutrophil function more selectively, since their CL-lum
IC50 values are more than fourfold lower than their CL-luc IC50 values.
Increased lipophilicity improves the inhibitory effect of ﬂavonoids on
the oxidativemetabolismof IC- and phorbolmyristate acetate-stimulated
neutrophils [12,39]. However, correlating the physicochemical property
and biological activity is no easy task. The inhibition of rabbit neutrophil
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inverted parabola [15]. In other words, upon increasing lipophilicity the
biological activity ﬁrst decreases to a minimum and then rises.
Increased lipophilicity of catechin derivatives [39] and acetylated
quercetin derivatives [37] augments their bioavailability and favors
their interaction with intracellular targets. Esteriﬁcation of ﬂuorescent
probes such as Fluo-3 and Fura-2 enhances the lipophilicity and intra-
cellular bioavailability of these derivatives. The ester form of the probe
readily crosses the plasmamembrane, and intracellular esterases cleave
the ester bond. This culminates in hydrophilic products that accumulate
in the cytoplasm [40]. Considering themechanismdescribed for ﬂuores-
cent probes, we believe that esterases partially hydrolyze the acetylated
3-phenylcoumarins, resulting in intracellular products with different bi-
ological actions from those of the totally hydroxylated or acetylated
compounds.
Comparing the inhibitory effect of the 3-phenylcoumarin deriva-
tives on neutrophil CL-lum and CL-luc, we observe that most com-
pounds (2, 5, 6, 8, 10, 19, and 20) inhibit CL-lum more strongly. This
suggests that the aforementioned derivatives do not signiﬁcantly act
at the beginning of neutrophil ROS production, but they probably affect
the latter steps of this process. To test this hypothesis, we evaluated the
ability of selected 3-phenylcoumarins to inhibit the neutrophil NADPH
oxidase and MPO activities, as well as their HOCl scavenging potential.
NADPH oxidase is an important therapeutic target in inﬂammatory
diseases involving neutrophils [9,41,42]. The 3-phenylcoumarin deriva-
tives 1, 5, 19, and 20, the strongest inhibitors of CL-luc, only slightly af-
fect (5–7%) O2 consumption by IC-stimulated neutrophils. Therefore,
these compounds virtually do not act on the assembly or catalytic activ-
ity of the NADPH oxidase complex, so they do not signiﬁcantly inhibit
O2•− generation by IC-stimulated neutrophils but probably function as
O2•− scavengers. Albeit small, the inhibitory effect of the tested com-
pounds on NADPH oxidase can help modulate ROS production by neu-
trophils in IC-mediated diseases, since large amounts of these cells
inﬁltrate into the inﬂammatory site [4,42].
To gain initial insight into the action of 3-phenylcoumarin deriva-
tives in the subsequent steps of ROS generation by IC-stimulated neu-
trophils, as measured by the CL-lum assay, we evaluated the inhibitory
effect of these derivatives on MPO activity and their HOCl scavenging
potential. We studied the inhibitory effect of the 3-phenylcoumarin de-
rivatives on MPO activity using a cell-free system and puriﬁed MPO, as
described in Experimental procedure section. Inhibition increases with
the number of free hydroxyl groups (19>5>1) on the molecule. How-
ever, the mono-hydroxylated 3-phenylcoumarin 1 is as effective as the
pentahydroxylated ﬂavonoid quercetin. Therefore, not only the number
but also the position of the hydroxyl group in a molecule inﬂuences its
ability to inhibit MPO activity, since compounds 19 and 1 bear two
and one o-dihydroxyl groups, respectively. These results agree with re-
ports highlighting the importance of the number and position of hy-
droxyl groups, especially the presence of the catechol group, for
efﬁcient inhibition of the catalytic activity of MPO [43] and horseradish
peroxidase [12,14]. In addition, the acetylated 3-pheylcoumarin deriva-
tives do not signiﬁcantly inhibit MPO activity, reinforcing the impor-
tance of free hydroxyls for this biological activity.
We also assayed the HOCl scavenging potential of the 3-
phenylcoumarin derivatives in a cell-free system. The ranking order of
the HOCl scavenging effect suggests that the number and position of
free hydroxyl groups are important. The catechol group signiﬁcantly
contributes to the HOCl scavenging effect of ﬂavonols [44] and the
free radical scavenging effect of ﬂavonoids [45], coumarins [46], and
3-phenylcoumarins [14,24]. Interestingly, acetylation of the free hy-
droxyls does not affect the HOCl scavenging potential of the tested
3-phenylcoumarins considerably. Such result agrees with literature re-
ports that o-diacetoxy-4-methylcoumarins display strong free radical
scavenging activity, which could be compared to the corresponding
o-dihydroxy parent structures [46,36]. Raj et al. [36] have suggested
that the acetyl group spontaneously hydrolyzes in aqueous medium,generating the active hydroxylated form; however, the exact mecha-
nism underlying the antioxidant effect of acetylated compounds re-
mains unexplained.
Luminol does not speciﬁcally detect ROS, so the measured CL-lum
results from luminol oxidation by different types of ROS [35]. Consid-
ering that MPO and HOCl are the most important mediators of
luminol oxidation (and CL-lum production) in activated neutrophils,
inhibition of MPO activity and HOCl scavenging might contribute to
the inhibitory effect of the 3-phenylcoumarin derivatives on the
CL-lum of IC-stimulated neutrophils. Although the acetylated com-
pounds do not inhibit the MPO activity in cell-free systems, intracel-
lular esterases can hydrolyze these compounds, yielding the active
hydroxylated product in the neutrophils.
The order of the inhibitory effects of the 3-phenylcoumarin deriva-
tives on the CL-lum and CL-luc of IC-stimulated human neutrophils
agrees with previous results on the screening of the modulatory effect
of these compounds on rabbit neutrophils [15]. The absolute IC50 values
and the relative inﬂuence of acetylation of free hydroxyl groups have lit-
tle interspecies (humans and rabbits) variation. However, most of the
3-phenylcoumarin derivatives studied here inhibit the human neutro-
phil CL-lum more than they inhibit the human neutrophil CL-luc, while
the opposite trend is detected for rabbit neutrophils. Together, these
data suggest that small cellular physiology differences between species
[47] can interfere in the structure–activity relationship analysis, al-
though the rabbit is an important experimental model for IC-mediated
diseases [48].
The results of the present work suggest that small differences in the
structural features of the 3-phenylcoumarin derivatives contribute to in-
hibition of the CL-luc and CL-lum of IC-stimulated human neutrophils.
Considering the set of compounds tested here, compound 5, bearing
the 6,7-dihydroxyl and the 3′,4′-methylenedioxyl groups, inhibits both
CL-lum and CL-luc more effectively, whereas the other compounds in-
hibit CL-lum more selectively. Their mechanism of action does not in-
volve inhibition of NADPH oxidase activity or cytotoxicity, but we
detected signiﬁcant inhibition ofMPOactivity andHOCl scavenging abil-
ity. This is just a preliminary analysis, so othermechanisms are probably
involved in the inhibition of neutrophil ROS generation and merit fur-
ther investigation.
Considering the important participation of neutrophil-derived
ROS in the pathogenesis of IC-mediated diseases and regulation of
acute and chronic inﬂammatory processes, our results can help devel-
op more potent and selective antioxidant and anti-inﬂammatory
drugs based on the 3-phenylcoumarin moiety.
4. Signiﬁcance
Some inﬂammatory diseases involve the deposition of immune
complexes (IC) in tissues. This event triggers intense neutrophil recruit-
ment and activation, with subsequent release of oxidant and lytic com-
pounds that damage the surrounding tissues. On the other hand,
reactive oxygen species (ROS) production by neutrophils is essential
for the host defense and regulation of acute and chronic inﬂammatory
responses. Therefore, modulating this neutrophil function is an impor-
tant therapeutic strategy tomanage inﬂammation and reduce the dele-
terious effects of ROS. Our research team has been investigating the
antioxidant and anti-inﬂammatory potential of 3-phenylcoumarin de-
rivatives, which have arisen as promising compounds to be used for
the aforementioned purpose. The present study reported themodulator
effect of ten 3-phenylcoumarin derivatives on the superoxide anion and
total ROS generation by IC-stimulated human neutrophils. We found
that most compounds did not signiﬁcantly act at the beginning of neu-
trophil ROS production process, since they did not signiﬁcantly inhibit
the NADPH oxidase activity. In fact, they affected the latter steps of
this process; the 3-phenylcoumarin derivatives that inhibited the over-
all neutrophil ROS generation process the most strongly also inhibited
MPO activity and scavenged HOCl. Interestingly, compound 5, which
392 M.F. Andrade et al. / International Immunopharmacology 15 (2013) 387–394bears 6,7-dihydroxyl and 3′,4′-methylenedioxyl groups, inhibits the
neutrophil ROS generation the most effectively, yielding similar IC50
values for both steps studied. In addition, the type, number, and posi-
tion of the hydroxyl and acetoxyl groups inﬂuenced the ability of
3-phenylcoumarin derivatives to decrease the ROS generation by
IC-stimulated neutrophils, but the structural features contributing to in-
hibition of the two steps of the process here investigated were a little
different. Together, the results of this study contribute to understand
the mechanism of action of 3-phenylcoumarin derivatives on neutro-
phils and also to develop more potent and selective therapeutic mole-
cules that could modulate ROS production by neutrophils in
IC-mediated inﬂammatory diseases.
5. Experimental procedure
5.1. Chemicals
Diphenyleneiodonium chloride (DPI), guaiacol, luminol (5-amino-2,
3-dihydro-1,4-phthalazinedione), lucigenin (bis-N-methylacridinium ni-
trate), N,N-dimethylformamide (DMF), ovalbumin, quercetin dihydrate
(3′,4′,3,5,7-pentahydroxyﬂavone), 3,3′,5,5′-tetramethylbenzidine (TMB),
taurine, Triton X-100, and Trypan Blue were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Dimethyl sulfoxide (DMSO), hy-
drogen peroxide (H2O2), human leukocyte myeloperoxidase (MPO,
EC 1.7.1.11), and p-aminobenzohydrazide (p-AB) were obtained
from Calbiochem (Merck KGaA, Darmstadt, Germany). The gelatin
(microbiological grade) was acquired from Difco Laboratories (Detroit,
MN, USA), and LDH Liquiform was provided by Labtest Diagnostica
(Lagoa Santa, MG, Brazil). All the other chemicals and solvents used in
this work were of analytical grade and purchased from commercial
sources.
5.2. 3-Phenylcoumarin derivatives
The 3-phenylcoumarin derivatives were synthesized and charac-
terized as previously described [14,32]. The identiﬁcation code of
the compounds is the same as the one employed in a previous work
[14] (Fig. 1).
5.3. Human neutrophils isolation
Twenty adult subjects in good general health and aged between
18 and 40 years were recruited according to the protocol approved
by the local Research Ethics Committee (CEP/FCFRP-USP, protocol
number 182). All the participants signed an informed consent prior
to the performance of any study-related procedure. Exclusion criteria
were as follows: (1) history of any acute or chronic disease, (2) recent
use of anti-inﬂammatory drugs, (3) recent history of alcohol or drug
abuse, or (4) active smoking.
Bloodwas collected from volunteers by venous puncture and placed
in Alsever solution (v/v), which served as anticoagulant. Neutrophils
were isolated by the method described by Lucisano and Mantovani
[49], with modiﬁcations [50]. The cell pellets were suspended in Hank's
balanced saline solution (HBSS) containing 0.1% (v/v) gelatin (HBSS–
gel). The cell preparations contained 80–90% neutrophils with viability
higher than 95%, as established by exclusion with Trypan Blue.
5.4. Cytotoxicity evaluation
The cytotoxic effect of the 3-phenylcoumarin derivatives on neutro-
phils was evaluated as described by Lucisano-Valim et al. [51]. Values in
parentheses refer to the ﬁnal concentrations in 0.5 mL of reaction.
Brieﬂy, aliquots of neutrophils (1×106 cells/mL) were incubated
with a 3-phenylcoumarin derivative (20 μM), quercetin (10 μM),
DMSO (0.1% v/v; vehicle), HBSS–gel (negative control), or Triton
X-100 (0.2% v/v; positive control) for 30 min, at 37 °C. The cell pelletswere suspended in HBSS–gel after centrifugation (755 ×g, 10 min,
4 °C), and the cellular viability was determined by the Trypan Blue
dye exclusion test, by counting a total of 200 cells for each sample.
The activity of cytosolic lactate dehydrogenase (LDH) released into
the supernatant was measured on the basis of absorbance changes at
340 nm for 2 min, at 37 °C (U2910 spectrophotometer, Hitachi Instru-
ments, Tokyo, Japan). The LDH Liquiform™ test kit was used in this
assay.
5.5. Immune complexes preparation
Precipitated immune complexes (IC) of anti-ovalbumin IgG anti-
body and ovalbumin were prepared from the equivalence zone, as de-
scribed in a previous work [49]. Total protein concentration in the
precipitate was determined by absorbance readings at 280 nm and
expressed as μg/mL. The IC were diluted in HBSS pH 7.2 for use.
5.6. Neutrophil chemiluminescence assay
The neutrophil chemiluminescence (CL) assay was performed in
96-well microplates using the procedure described by Lucisano-Valim
et al. [51], with slight modiﬁcations. The concentration of each compo-
nent in the reaction medium (0.2 mL) is indicated in parentheses
below. Lucigenin, luminol, quercetin, and 3-phenylcoumarins stock so-
lutions were prepared in DMSO and diluted in HBSS–gel prior to use.
Aliquots of neutrophils (1×106 cells/mL)weremixedwith the chemi-
luminescence (CL) probe [luminol (0.1 mM) or lucigenin (0.1 mM)] and
the tested compound — a 3-phenylcoumarin derivative (0.01–20 μM),
quercetin (0.01–10 μM; reference compound), DMSO (0.1% v/v; vehicle),
or HBSS–gel (control). Themixturewas incubated at 37 °C for 3 min, and
the reaction was initiated by adding IC (60 μg/mL). The luminol- and
lucigenin-enhanced chemiluminescence (CL-lum and CL-luc, respective-
ly)weremeasured in amicroplate luminometer (LB 960 Centro, Berthold
Technologies, Bad Wildbad, Germany), and the light emission was
recorded in cps (photon counts per second) for 20 min, at 37 °C. The per-
centage of CL inhibition by each sample was calculated using the formula
[1−(AUCsample/AUCcontrol)]×100. AUC is the area under the time–course
curve, and it is used to determine IC50 values (concentration that inhibits
50% of the neutrophil CL).
5.7. NADPH oxidase activity
The NADPH oxidase activity was assessed by measuring O2 con-
sumption by IC-stimulated neutrophils according to a previously de-
scribed procedure [50]. Values in parentheses refer to the ﬁnal
concentrations in 0.5 mL. Brieﬂy, the basal O2 consumption by neutro-
phils (4×106 cells/mL) was measured in the presence of the tested
compound — a 3-phenylcoumarin derivative (20 μM), quercetin
(20 μM; reference compound), DPI (1 μM; positive control), DMSO
(0.1% v/v; vehicle), or HBSS–gel (control)— for 7 min, at 37 °C. The re-
action was started by adding IC (240 μg/mL) to the neutrophils/tested
compound mixture, and O2 consumption was measured for 7 min, at
37 °C. Oxygen consumption by NADPH oxidase was determined by cal-
culating the difference between the rates before and after IC addition.
5.8. Myeloperoxidase activity
The modulator effect of the 3-phenylcoumarin derivatives on
human MPO activity was evaluated using the method of Regasini et
al. [43], with modiﬁcations. Hydrogen peroxide working solutions
were prepared daily, and the H2O2 concentration was calculated by
measuring its absorbance at 240 nm (ε=43.6 M−1·cm−1) [52].
The MPO activity was assayed in 96-well microplates, and values in
parentheses refer to theﬁnal concentrations in 0.2 mL. Reactionmixtures
containing PBS (10 mM sodium phosphate buffer pH 7.4, 140 mMNaCl,
10 mM KCl), guaiacol (30 mM), MPO (2 nM), and the tested compound
393M.F. Andrade et al. / International Immunopharmacology 15 (2013) 387–394– a 3-phenylcoumarin derivative (20 μM), quercetin (20 μM; reference
compound), p-aminobenzohydrazide (20 μM; positive control), DMSO
(0.1% v/v, vehicle), or PBS (negative control) — were incubated at
25 °C, for 2 min. The reaction was initiated with H2O2 (500 μM), and ab-
sorbance changes were recorded at 470 nm for 2 min, at 25 °C (Varian
Cary 50 Bio UV/Visible spectrophotometer, Sparta, Australia). MPO activ-
ity was calculated from the initial linear rate of the reaction.
5.9. Hypochlorous acid scavenging assay
The HOCl scavenging potential of the 3-phenylcoumarin derivatives
was assessed by the method of Dypbukt et al. [52], with modiﬁcations.
Domestic sodium hypochlorite, purchased as approximately 350 mM
solution in NaOH, was neutralized by dilution in PBS immediately be-
fore use. The hypochlorite concentrationwas determined bymeasuring
its absorbance at 292 nm in a solution at pH 12 (ε=350 M−1·cm−1).
Stock solutions of 3-phenylcoumarin derivatives were prepared in
DMF and diluted in PBS for use.
The working solution of the tested compound— a 3-phenylcoumarin
derivative (0.01–12 μM), quercetin (0.01–12 μM), DMF (0.03% v/v, vehi-
cle), or PBS (control)—was added to HOCl (50 μM) and allowed to react
for 10 min. Taurine (5 mM)was then added to the reactionmedium, and
taurine chloraminewas detected after 5 min by rapidlymixing thedevel-
oping reagent (2 mM TMB in 400 mM acetate buffer pH 5.4 containing
10% DMF and 100 μM KI). The mixture was incubated for 5 min and
the absorbance was recorded at 650 nm in a 96-well microplate reader
(Varian Cary 50 Bio UV/Visible spectrophotometer, Sparta, Australia).
All the reaction steps were conducted in the dark at 25 °C.
5.10. Data analysis
Experimental data were processed and analyzed with the aid of
the GraphPad Prism Software (version 3.00 for Windows, GraphPad
Software Inc., San Diego, CA, USA). Statistical analysis was performed
by Student's t test (for two groups) or analysis of variance (ANOVA)
followed by Tukey's test (for three or more groups), as indicated in
the legends. pb0.05 was considered signiﬁcant.
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